Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Broker sentiment is moderately bullish: Six of eight analysts rate Cullinan Therapeutics a buy, while one rates it a hold and one a sell. The average 12-month price target is $32.14, well above the reported share price of $19.60.
• Shares have risen substantially but remain unprofitable: CGEM is near its 52-week high of $19.94, with a market capitalization of $1.26 billion. The company reported a quarterly loss of $0.81 per share, narrowly missing consensus estimates, and analysts expect a full-year loss of $3.03 per share.
• Institutional ownership is strong, though an insider recently sold shares: Institutions and hedge funds own 86.31% of the stock, with several firms increasing their positions. Separately, insider Jennifer Michaelson sold 8,000 shares for approximately $142,560.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $32.1429.

A number of research firms have recently issued reports on CGEM. Weiss Ratings restated a "sell (d-)" rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wedbush reiterated an "outperform" rating and set a $37.00 price target on shares of Cullinan Therapeutics in a report on Thursday, June 11th. Wall Street Zen lowered Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Cullinan Therapeutics in a research report on Monday, June 8th. Finally, BTIG Research increased their price objective on Cullinan Therapeutics from $38.00 to $39.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th.

Cullinan Therapeutics Price Performance

CGEM stock opened at $19.60 on Thursday. The firm has a market capitalization of $1.26 billion, a P/E ratio of -6.32 and a beta of 0.01. Cullinan Therapeutics has a 52-week low of $5.68 and a 52-week high of $19.94. The company's 50 day simple moving average is $16.81 and its 200-day simple moving average is $14.99.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.01). Sell-side analysts predict that Cullinan Therapeutics will post -3.03 EPS for the current fiscal year.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $30 target for Cullinan Therapeutics (CGEM). The target remains meaningfully above the recent share price, providing a bullish valuation signal and likely supporting the stock’s recent strength.
• Neutral Sentiment: The analyst expects Cullinan to remain unprofitable but sees quarterly losses narrowing gradually in 2027, with estimated EPS of $(0.77) in Q1, $(0.78) in Q2, $(0.80) in Q3 and $(0.82) in Q4. Full-year 2027 EPS is projected at $(3.17), compared with an estimated $(3.53) loss in 2026.
• Neutral Sentiment: A reported short-interest figure of zero shares and a zero-day days-to-cover ratio offers no meaningful indication of bearish positioning. The data appears unreliable or incomplete rather than evidence of an absence of short sellers.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a $(3.53) loss from $(3.42), cut Q3 2026 EPS to $(0.90) from $(0.87), and reduced Q4 2026 EPS to $(0.93) from $(0.90). These revisions point to weaker-than-previously-expected profitability and could limit gains despite the bullish price target.

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the sale, the insider directly owned 162,844 shares of the company's stock, valued at $2,901,880.08. This represents a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of hedge funds have recently modified their holdings of CGEM. Dynamic Technology Lab Private Ltd acquired a new stake in Cullinan Therapeutics during the first quarter valued at $163,000. Jane Street Group LLC increased its position in Cullinan Therapeutics by 145.9% in the 1st quarter. Jane Street Group LLC now owns 34,396 shares of the company's stock worth $260,000 after purchasing an additional 109,413 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Cullinan Therapeutics in the 1st quarter worth about $618,000. Creative Planning increased its position in Cullinan Therapeutics by 222.2% in the 2nd quarter. Creative Planning now owns 41,723 shares of the company's stock worth $314,000 after purchasing an additional 28,773 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Cullinan Therapeutics by 122.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 97,069 shares of the company's stock worth $731,000 after purchasing an additional 53,522 shares in the last quarter. 86.31% of the stock is owned by institutional investors and hedge funds.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source